Sales strategy experts join forces for the Pharmaceutical Sales Force Effectiveness Conference

eyeforpharmaOver 70 biggest movers and shakers in pharmaceutical sales strategy join together to speak at the 6th annual Sales Force Effectiveness Conference on 2-4th April, 2008 in Barcelona. They will be discussing business-critical issues such as the impact of sales force cuts, changes in the European healthcare environment and customer base and how to do more with less when it comes to sales strategy.

With over 800 senior level pharmaceutical executives attending during three days of knowledge-packed conference, the event is know as THE meeting place for pharma sales strategy innovators.

In a statement Miss Izzy Wakeling, the conference organiser said: "We are so proud to be part of this ongoing improvement of pharma's sale forces, their conduct and their success in generating top-line revenue for the industry. With the European healthcare environment producing so many new challenges and dynamic changes, sales and marketing activities in pharmaceutical companies need to really start responding to this healthcare climate change. This conference provides a perfect learning, knowledge sharing and discussion platform to overcome these challenges."

The Keynotes include:

  • Mike Capaldi, Associate VP of Training and Development, Sanofi-Aventis
  • Saila Roitto, Senior Project Manager, Commercial Operations, Novartis
  • Tim Townend, Sales Training Director, Bristol Myers Squibb
  • Nick Pope- Director of Sales Training, Bausch & Lomb
  • Paul Kusters, Associate Director Sales Force Effectiveness and Training Europe, UCB
  • And the rest are now available to see on the official website: www.sfeeurope.com

The 3 day conference consists of presentations, workshops, roundtables, speed-networking, cocktail receptions and VIP dinners and is seen as the leading conference and meeting place for sales strategy executives in the pharmaceutical industry, with over 650 delegates attending the Monaco conference in 2007. The wide range of topics at the conference include: Key Account management, CRM optimisation, Integrated Selling models, Customer Relationship Strategies, First Line Management Coaching, eLearning, Wireless Technologies, eDetailing, Web 2.0, Targeting and Segmentation and Performance Management and how they can be used in the pharmaceutical industry to increase the effectiveness of a company's sales force in an ever changing and challenging healthcare environment.

Further updates, full information on presentations and speakers, and details on other ticket options can all be found by visiting www.SFEeurope.com.

About the eyeforpharma Sales Force Effectiveness Conference Europe
The eyeforpharma Sales Force Effectiveness Conference was established 6 years ago and is now the world's leading and most established sales strategy conference for the pharmaceutical industry. With over 650 attendees participating in Monaco in 2007 and over 800 expected in 2008 in Barcelona it is seen as the meeting and learning place for senior-level sales executives from across the world to learn how they can increase the effectiveness of their sales force in an ever changing and constantly challenging healthcare environment. Find out more at www.SFEeurope.com.

About eyeforpharma
eyeforpharma is a leading global source of information for the pharmaceutical industry. Our reputation has been built on quality, in-depth conferences that have distinguished themselves from competitors by the depth and breadth of research we put into each conference to ensure it is covering the hottest and most pertinent issues of the industry. Months are spent talking directly to senior executives in the industry, as well as relevant consultants and journalists and well respected solutions providers. For more information, please visit www.eyeforpharma.com.

Most Popular Now

Lilly will supply an additional 150,000 doses of b…

Eli Lilly and Company (NYSE: LLY) announced a modified purchase agreement with the U.S. government to supply an additional 150,000 doses of bebtelovimab for approximately...

Bayer to sell men's health product Nebido™ to Grün…

Bayer and Grünenthal have entered into a definitive agreement regarding the sale of Bayer's men's health product Nebido™ (testosterone undecanoate), for a purchase price ...

Pfizer and BioNTech complete submission to Europea…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced they have completed a submission to the European Medicines Agency (EMA) for an Omicron-adapted biva...

The fourth COVID-19 vaccine reduces the risk of de…

A new study by Tel Aviv University and Ben Gurion University of the Negev, in collaboration with the Israeli Ministry of Health, has found that the fourth COVID-19 vaccin...

Vaccine protection against COVID-19 short-lived, b…

Since COVID-19 vaccines first became available to protect against infection and severe illness, there has been much uncertainty about how long the protection lasts, and w...

AstraZeneca to acquire TeneoTwo and its clinical-s…

AstraZeneca announced an agreement to acquire TeneoTwo, Inc. (TeneoTwo)i, including its Phase I clinical-stage CD19/CD3 T-cell engager, TNB-486, currently under evaluatio...

Demonstration of a potent, universal coronavirus m…

The SARS-CoV-2 that causes COVID-19 has killed 6.3 million people worldwide since 2019, painfully highlighting the vulnerability of humanity to novel coronaviruses. Re...

Research shows investigational drug fosters nerve …

Scientists from the University of Birmingham have shown that a brain-penetrating candidate drug currently in development as a cancer therapy can foster regeneration of da...

NIH launches clinical trial of mRNA Nipah virus va…

The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has launched an early-stage clinical trial evaluating an inv...

Anti-inflammatory compound shows potential in trea…

An anti-inflammatory compound may have the potential to treat systemic inflammation and brain injury in patients with severe COVID-19 and significantly reduce their chanc...

Vaccine-induced immune response to omicron wanes s…

Although COVID-19 booster vaccinations in adults elicit high levels of neutralizing antibodies against the Omicron variant of SARS-CoV-2, antibody levels decrease substan...

SARS-CoV-2 hijacks nanotubes between neurons to in…

COVID-19 often leads to neurological symptoms, such as a loss of taste or smell, or cognitive impairments (including memory loss and concentration difficulties), both dur...